HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615
Debt
Debt-to-Equity Ratio0.35
Current Ratio9.50
Quick Ratio9.29
Price-To-Earnings
Trailing P/E Ratio-2.28
Forward P/E Ratio-5.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.76 million
Price / Sales7.86
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-34.00
Profitability
EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-81.10%
Return on Equity-132.67%
Return on Assets-47.67%
Miscellaneous
Employees98
Outstanding Shares28,420,000
Market Cap$113.69 million
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) issued its earnings results on Thursday, August, 9th. The medical research company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The medical research company had revenue of $4.91 million for the quarter, compared to analyst estimates of $5.30 million. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. View HTG Molecular Diagnostics' Earnings History.
When is HTG Molecular Diagnostics' next earnings date?
What price target have analysts set for HTGM?
3 Wall Street analysts have issued 1-year price objectives for HTG Molecular Diagnostics' shares. Their forecasts range from $7.00 to $7.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics.
What is the consensus analysts' recommendation for HTG Molecular Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics.
What are Wall Street analysts saying about HTG Molecular Diagnostics stock?
Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
- 1. HC Wainwright analysts commented, "We note that the company entered into the first amendment earlier this month, which involves performing collaborative development services for what is expected to be a multi-stage project that leads to a potential NGS-based companion diagnostic assay in support of the therapeutic programs at Bristol-Myers Squibb Co. (BMY; not rated). HTG currently has two development programs ongoing in the statement of work under the master agreement with QIAGEN. The amendments allow the use of IUO assays in subsequent prospective and retrospective clinical trials for multiple indications, which are the next steps in the company’s immuno-oncology (I/O) collaboration. In our view, HTG now has more shots on goal, represented by the potential commercialization of companion diagnostics for therapeutics being developed by biopharma partners." (8/16/2018)
- 2. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (8/14/2018)
Who are some of HTG Molecular Diagnostics' key competitors?
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. Timothy B. Johnson, CEO & Director (Age 57)
- Mr. John L. Lubniewski, Pres & COO (Age 54)
- Mr. Shaun D. McMeans, Sr. VP, CFO, Sec. & Treasurer (Age 56)
- Dr. Debra A. Gordon, Sr. VP and Chief Legal Counsel (Age 58)
- Dr. Patrick C. Roche, Sr. VP of R&D (Age 65)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Has HTG Molecular Diagnostics been receiving favorable news coverage?
News headlines about HTGM stock have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. HTG Molecular Diagnostics earned a news impact score of 0.18 on Accern's scale. They also gave media coverage about the medical research company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for HTG Molecular Diagnostics.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (12.27%), Stonepine Capital Management LLC (5.94%), Putnam Investments LLC (4.88%), Granahan Investment Management Inc. MA (3.22%), Spark Investment Management LLC (0.72%) and GSA Capital Partners LLP (0.70%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Which institutional investors are buying HTG Molecular Diagnostics stock?
HTGM stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Putnam Investments LLC, Spark Investment Management LLC, GSA Capital Partners LLP, Granahan Investment Management Inc. MA, Acadian Asset Management LLC, BlackRock Inc. and FMR LLC. View Insider Buying and Selling for HTG Molecular Diagnostics.
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $4.08.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $113.69 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
